Treating serious infections
Bacterial resistance is increasing worldwide, making treatment options more limited. The World Health Organization (WHO), in 2010, characterized bacterial resistance as one of the three greatest threats to human health. In a 2013 report, “Antibiotic Resistance Threats in the United States,” the U.S. Centers for Disease Control and Prevention (CDC) warned of the complex problem of antibiotic resistance and the potentially catastrophic consequences of inaction.
When first-line and then second-line antibiotic treatment options are limited by resistance or are unavailable, healthcare providers are forced to use antibiotics that may be more toxic to the patient and frequently more expensive and less effective. The development of new antibiotics to meet this threat is a matter of urgency. Nabriva is developing novel antibiotics, with a focus on pleuromutilins, which is a new class of antibiotics for systemic administration in humans.
Community acquired bacterial pneumonia
Community-acquired bacterial pneumonia is the leading cause of infectious deaths and the second most common cause of hospitalization in the United States. Based on a combined analysis of the U.S. Centers for Disease Control and Prevention’s 2007 National Ambulatory Medical Care Survey and 2013 data from the Healthcare Cost and Utilization Project, Nabriva Therapeutics estimates that more than 5 million adults annually go to a site of care for CABP treatment in the United States. Based on 2013 data from the Healthcare Cost and Utilization Project, Nabriva Therapeutics estimates that approximately 3 million of these adult CABP patients are diagnosed in a hospital setting, where most are then treated as in-patients with IV and oral antibiotics or as out-patients with oral antibiotics following hospital discharge or release.